651 filings
Page 2 of 33
8-K
sgwamvwrn14g7g 64mf2
19 Jan 24
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
5:14pm
424B5
ts6p3kgtjzl68m
17 Jan 24
Prospectus supplement for primary offering
7:18pm
8-K
9bik zgjd
16 Jan 24
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
5:18pm
8-K
jdsrz8fo
16 Jan 24
Vaxart, Inc. Announces Management Change
9:19am
8-K
jl0gk1gn 7b
2 Nov 23
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
4:11pm
8-K/A
oft8mhkacuhk
23 Oct 23
Submission of Matters to a Vote of Security Holders
5:09pm
8-K
cwyjsugz wxbkqmw
23 Oct 23
Amendments to Articles of Incorporation or Bylaws
5:01pm
8-K
qe5rb0ihfyx0ulfev4
6 Sep 23
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
4:43pm
8-K
2jcd odjao4
3 Aug 23
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
4:20pm
8-K
9efs6j j2l
26 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:20pm
8-K
xzxpqbhvwn
10 Jul 23
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
4:12pm
8-K
aqvttz
28 Jun 23
Submission of Matters to a Vote of Security Holders
4:22pm
DEFA14A
1rxly9
21 Jun 23
Additional proxy soliciting materials
5:18pm
8-K
od9nt1v9d0ky yi1bl6
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm
424B5
ukc7qv3 yo8elg
8 Jun 23
Prospectus supplement for primary offering
4:17pm
424B5
we6qpgxzspkdng655cml
6 Jun 23
Prospectus supplement for primary offering
5:21pm
8-K
qo5dxm0v5hpxn4jl
6 Jun 23
No Vaccine Related Serious Adverse Events (SAEs) reported to date
8:07am
8-K
5efzea auq0oq
25 May 23
Other Events
4:31pm